International Foundations of Medicine Exam Program (IFOM) FMALL Demo by dave_baker39

Ezetimibe inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, thereby reducing cholesterol absorption and lowering LDL cholesterol by an additional ~15-20% when added to statin therapy. The IMPROVE-IT trial demonstrated that adding ezetimibe to simvastatin in patients with a recent acute coronary syndrome further reduced LDL cholesterol and produced a modest but statistically significant reduction in composite cardiovascular events. Monotherapy with ezetimibe is not equivalent in magnitude of benefit to statin therapy, and ezetimibe combined with statins is well tolerated with no substantially increased hepatotoxicity above that of statins alone.